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Abstract 
Based on recent studies, the most common and lethal type of “ovarian” cancer, 
high grade serous carcinoma (HGSC), is thought to originate in the fallopian tube 
epithelium rather than from the ovarian surface epithelium [1]. To study the 
pathogenesis of HGSC in a mouse model, the Cho lab developed Ovgp1-iCreERT2 
mice, in which the Ovgp1 promoter is used to control expression of tamoxifen (TAM)-
regulated Cre recombinase in the murine equivalent of human fallopian tube epithelium 
(oviductal epithelium).  TAM-treated Ovgp1-iCreERT2 mice carrying various genetically 
engineered tumor suppressor gene alleles were used to study effects of inactivating 
different combinations of tumor suppressor genes in the oviductal epithelium.   
Specifically, Brca1, Trp53, Rb1, and Nf1 were selected because they are often 
inactivated in human HGSCs and lead to genetic instability and tumor development [2].  
In order to characterize oviductal tumors arising in our genetically engineered mouse 
models and verify how comparable they are to human HGSCs, targeted exome 
sequencing was used to analyze the 32 most commonly mutated genes in human 
HGSC.  Our analysis employed the sequence data to assess DNA copy number 
alterations (CNAs) in the mouse tumors.  Unsupervised hierarchical clustering was used 
to group tumors based on their CNA profiles.  Like human HGSCs, the mouse tumors 
show a high level of genomic instability, with many widely distributed CNAs.  In addition, 
the tumors acquire other genetic changes characteristic of human HGSCs, such as 
amplification of cMyc and deletion of Pten.   
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Introduction 
For women worldwide, ovarian cancer is the seventh most common cause of 
cancer-related death [3]. Among these cases, the most prevalent and deadly type is 
high-grade serous carcinoma (HGSC) [4]. While it was originally believed that the cell of 
origin of these cases would be found in the ovaries, research has shown that most 
HGSCs likely originate in the fallopian tube [5]. For this reason, the Cho lab has been 
studying epithelial transformation in the murine equivalent, the oviduct.   
The Cho lab has generated genetically engineered mice, henceforth referred to 
as Ovgp1-iCreERT2 mice, in which the Ovgp1 promoter is used to drive expression of 
tamoxifen-regulated Cre recombinase specifically in the oviductal epithelium [6]. When 
LoxP sites are placed within genes of interest, the sequence between them can be 
inverted, deleted or translocated depending on the orientation of the LoxP sites.  
Unlike experiments using knockout mice with germline deletions, the Cre-Lox 
system can allow for targeted, tissue specific, inducible knockouts [7]. In our case, 
Ovgp1-iCreERT2 mice were crossed with mice that contained different combinations of 
specific Cre-inducible (floxed) tumor suppressor genes (Trp53, Rb1, Brca1, Nf1, Pten, 
Apc, Arid1a). It was found that Ovgp1-iCreERT2 mice carrying different combinations of 
floxed genes develop HGSC-like oviductal tumors after transient treatment with 
tamoxifen [8].  Specifically, we generated mice targeted for loss of Brca1, Trp53, and 
Rb1 (BPR); Brca1, Trp53, Rb1 and Nf1 (BPRN); Brca1, Trp53 and Pten (BPP); Apc and 
Pten (AP); and Apc, Pten, and Arid1a (APA). 
Figure 1 shows an example of the typical progression of the disease in BPRN, 
BPR and BPP mice as seen by formation of serous tubal intraepithelial carcinomas 
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(STIC) which progress 
to HGSC or its variant 
Malignant Mixed 
Mullerian Tumor 
(MMMT), and later 
metastasize to other 
regions [9].  
 To help determine how closely our mouse models recapitulate the molecular 
features of human HGSC, we performed 
targeted exome next generation sequencing 
(NGS) on a large number of oviductal tumors 
arising in our mice [10].  A list of the most 
commonly mutated genes found in human 
HGSC is provided in Table 1 [11]. We created 
a targeted exome panel to sequence the mouse homologs of these genes in tumor and 
normal samples from our various oviductal cancer models.   
 
 
 
 
 
 
 
Table 1: Genes frequently mutated in human 
HGSCs identified by large scale sequencing and 
copy number analysis (TCGA)  
	
Figure 1: Typical progression of oviductal HGSC as seen in the mouse  
Pik3ca	
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Materials and Methods 
Genotyping of Mouse Samples 
Polymerase chain reaction (PCR) using allele specific primers was performed to confirm 
the presence of desired engineered alleles (normal tail DNA) in each mouse and to 
confirm inactivation of engineered alleles in tumor DNA.  PCR products were analyzed 
by conventional gel electrophoresis. 
 
Mouse Tissue Histopathology 
Tissues from euthanized mice were fixed in formalin and embedded in paraffin.  The 
oviducts and ovaries were then serially sectioned in their entirety.  5 µm sections were 
cut using a microtome and mounted on glass slides. Alternate sections were stained 
with hematoxylin and eosin (H&E) in order to visualize any cancerous lesions in the 
tissue. H&E stained slides were then used as guides for selecting the particular areas of 
interest in the tissues from which DNA was isolated. 
 
Immunohistochemical staining of mouse tissues 
Alternate sections that were not stained with H&E were routinely saved for 
immunohistochemical (IHC) staining as seen in Figure 6.  IHC was used to confirm up- 
or down-regulation of selected genes that were shown to have copy number alterations 
(e.g., amplification or deletion) according to the NGS results. Antigen retrieval was 
performed by microwaving the slides in citrate buffer (pH 6.0; Biogenex, San Ramon, 
CA) for 15 minutes. Endogenous peroxidase activity was quenched with 6% hydrogen 
peroxide in methanol. Staining was visualized with 3,3′-diaminobenzidine 
tetrahydrochloride and counterstaining with haematoxylin. Primary antibody used was 
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rabbit anti-PTEN (138G6/cat#9559, 1:400, Cell Signaling Technology, Inc., Danvers, 
MA). 
 
Isolation of DNA and RNA from Formalin-Fixed Paraffin Embedded (FFPE) 
Tissues 
 
The Qiagen AllPrep FFPE DNA/ RNA kit was used to isolate DNA and RNA from the 
tumor and normal samples. This multistep process allows for simultaneous DNA and 
RNA isolation through a series of washes and elution. Using a spectrophotometer, DNA 
and RNA were analyzed after running a blank as a control, and each sample’s 
concentration and quality were measured. Because our samples were isolated from 
FFPE tissues, the quality and quantity of nucleic acid was quite variable. Often, there 
was a very low concentration of DNA or there had been degradation over time. When 
necessary, processing of samples was modified to ensure that there would be as high a 
quality of DNA as possible. Specifically, sections of the paraffin embedded samples 
were cut slightly thicker (10 µm) or multiple slides made from a particular sample were 
used when the tumors were especially small from which DNA was being isolated. 
Ultimately, sufficient quantities of purified DNA and RNA were obtained from each 
sample. 
 
Targeted exome Next Generation Sequencing (NGS) of normal and tumor DNA 
samples  
 
In order to analyze DNA alterations in the tumors arising in our various genetically 
engineered mouse models of oviductal cancer, we performed multiplexed PCR-based 
NGS from 15 normal and 81 tumor DNA samples. Dr. Scott Tomlins (University of 
Michigan Department of Pathology) and his lab were instrumental in providing the tools 
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for this analysis and assisting with the data analysis.  Specifically, Tomlins designed a 
custom Ampliseq panel (1,445 amplicons targeting ~144kb) targeting the complete 
coding sequence of the mouse homologs of the 32 most significantly mutated 
(oncogenic and deleterious) and amplified/deleted genes in human HGSCs based on 
The Cancer Genome Atlas (TCGA) as shown in Table 1 [10]. Barcoded, mxNGS libraries 
were generated from 20 ng DNA per tumor, using this custom mouse Ampliseq panel and 
the Ion Ampliseq Library kit 2.0; sequencing was performed on an Ion Torrent Proton 
sequencer as described [11].  The data generated by targeted NGS can identify somatic 
or inherited mutations such as point mutations, small insertions or deletions, and copy 
number alterations (CNAs). 1445 amplicons were targeted and 96 samples were 
sequenced, 94 of which passed the library QC metrics (14 normal, 80 tumor).  
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Results 
 In order to confirm the genotypes of mice included in this analysis, allele specific 
PCR was used to verify the presence of the desired floxed alleles in tail DNA and Cre-
mediated recombination of these alleles in matched tumor DNA.  An example of such 
an analysis is shown in Figure 2.  This particular example shows that in mice carrying 
one floxed and one wild type Rb1 
allele, matched tumors often show 
deletion of the wild type allele in 
addition to recombination of the 
floxed allele.   
Targeted exome NGS sequencing was performed on DNA samples isolated from 
14 normal and 80 tumor samples (51 BPRN, 4 BPR, 5 BPN, 12 BPP, 4 AP, and 4 APA).  
In some cases, more than one tumor sample was obtained from a single mouse (e.g., 
right and left oviductal tumors, metastatic tumor).  We performed somatic copy number 
profiling from the mouse samples based on NGS data for the genes shown in Table 1.  
Notably, these genes are widely distributed throughout the mouse genome, including 15 
of the 19 mouse autosomes.  
Figure 3 shows examples of amplicon sequencing data from representative 
tumors arising in BPRN mice (Figures 3A and 3B) and from normal tissue (Figure 3C). 
Since BPRN mice have floxed alleles of Brca1, Trp53, Rb1 and NF1, the tumors show 
deletions of the expected regions of each of these genes (boxed regions).  These 
deletions are not observed in normal tissue from a BPRN mouse.  In addition to 
Figure 2: Example of PCR analysis confirming the successful 
genetic engineering of floxed and deleted Rb1 alleles in mouse 
tumor samples paired with their respective tail DNA 
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widespread copy number gains and losses not seen in the normal tissue sample, the 
tumors acquire other 
somatic alterations observed 
in a subset of human 
HGSCs, such as high-level 
amplification of cMyc (Figure 
3A) and biallelic deletion of 
Pten (Figure 3B).   
Importantly, 
widespread copy number 
alterations are a hallmark of 
human HGSCs that is 
recapitulated by tumors 
arising in our genetically 
engineered mice.  
Unsupervised hierarchical 
clustering of the CNA 
profiles was performed, in 
which samples with more 
similar CNA profiles are 
grouped together.  The data 
from each mouse and all of 
Figure 3: DNA copy number alterations in representative tumor and 
normal tissue samples. (A) Tumor from BPRN mouse shows 
amplification of Myc and chromosome 3 gain. (B) Tumor from a 
different BPRN mouse shows gain of chromosome 15 and deletion 
of Pten (C) a normal tissue sample with mean bars around 0 
indicating no DNA copy number alterations.  Sequenced genes are 
shown at bottom of each panel and each amplicon is represented by 
a colored dot.  Floxed regions are shown separately from the non-
floxed region of engineered genes.   
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the genes analyzed were compiled into a large scale heat map shown in Figure 4.  
From right to left, columns show the specific engineered alleles possessed by each 
mouse, abbreviated genotype (i.e., BPRN, BPP, AP, APA), type of lesion histology, site 
H
is
to
lo
gy
 
Figure 4: Heat map generated by NGS showing amplifications and deletions of targeted genes. 94 samples are 
shown in the map and 32 genes were analyzed  
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of the tumor or normal sample, and which samples are from the same mouse as coded 
by color. 
 In the heat map, copy number gains are indicated in red and losses in blue with 
color intensity reflecting the magnitude of gains and losses.  The BPRN mice are 
clustered together and show obvious blue regions corresponding to deletions of the 
floxed portions of Brca1, Trp53, Rb1 and Nf1. BPP mice also cluster together and show 
deletion of floxed portions of Brca1, Trp53 and Pten.  Tumors with deletions of Apc, 
Pten, +/- Arid1a also cluster together (AP and APA).   
Finally, there are 2 different groups of normal samples which are identified by the 
gray colored boxes under the histology column. While at first the separation of the two 
normal groups was unexpected, the 3 that were grouped apart from the other normal 
samples have a germline deletion of Brca1 and cluster more closely to the BPRN 
tumors than to the other normal tissues based on CNA profile.  This distinction helps to 
validate the unsupervised nature of the cluster analysis.  Additional genes that were 
deleted or amplified in the tumor samples can be seen by blocks of deep red or blue 
that appear in several other areas that were not specifically targeted by Cre-
recombinase.  
Interestingly, we noticed that there were a number of samples in the BPRN group 
with a reduction in Pten gene copy number even though we did not target Pten for 
deletion in these mice. In order to confirm these results, PCR was performed to verify 
Pten loss in the tumor samples compared to matched normal samples. Figure 5 shows 
that the band corresponding to the wild type allele of Pten that was clearly present for 
the normal samples is absent in the paired tumor samples. The 14433 samples were 
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isolated from a mouse that was engineered to be heterozygous for BPRN, meaning 
there was one floxed allele of each Brca1, Trp53, Rb1 and Nf1 and the other was a wild 
type allele (Supplemental Figure S1). 
The data shown in Figure 
5 confirm deletion of Pten in the 
tumor and metastasis samples 
(non-specific bands appear in 
the lanes corresponding to the 
tumor samples). Mouse 2405, 
was engineered with genotype 
Brca1flox/flox, Trp53flox/flox, Rb+/+, 
Nf1flox/+ (Supplemental Figure 
S1). Like the tumors arising in mouse 14433, wild type Pten was deleted in the tumor 
sample from mouse 2405.  
To further confirm deletion of Pten in the tumor samples from mice 14433 and 
2405, expression of PTEN protein was analyzed using IHC staining (Figure 6).  Figure 
6A shows loss of PTEN expression in a tumor from an APA mouse with confirmed 
deletion of Pten.  A section of a tumor from an BPP mouse is stained in Figure 6B.  
Figure 6C shows PTEN IHC staining of a BPRN tumor with somatic deletion of Pten 
while a tumor without Pten deletion that retained normal expression of PTEN is shown 
in Figure 6D. These data show that tumors with somatic deletion of Pten lose 
expression of PTEN protein, a feature often seen in human HGSCs [12].  
Figure 5: PCR of normal tissue samples paired with tumor samples 
in selected BPRN mice showing Pten loss. For sample 14433, LT 
indicates a tumor isolated from the left oviduct and MT indicates 
tumor isolated from a metastasis. Sample 2405 showed presence of 
Pten allele in normal tissue compared to the tumor. Water (no DNA) 
was used as a negative control. 
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In addition, according to the heat map, Myc was seen to have increased copy 
numbers in several BPRN mice. Again, even though we did not genetically manipulate 
the mice with regard to the Myc gene, the genetic instability of BPRN mice resulted in 
further mutations causing the loss of additional genes. The human model of HGSC 
follows the same pattern and tends to acquire additional copies of Myc resulting in 
upregulation [13].  
The NGS data also showed partial, rather than complete, Cre-mediated deletion 
of Brca1 in most of the tumors arising in mice carrying homozygous floxed Brca1, 
Figure 6: Immunohistochemical staining for PTEN expression. (A) shows a representative section of a tumor from 
an APA mouse #14593 in which the Pten allele was targeted for deletion and shows little positive staining for the 
protein. (B) is a section from a BPP mouse #15073 which was also targeted for Pten deletion and also shows little 
positive staining. (C) is a section from tumor of BPRN mouse #14433 that showed copy number losses of Pten and 
(D) is a positive control mouse #14396. 
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Trp53, and Pten 
alleles (BPP mice) 
which was 
unexpected. In 
order to confirm 
the results seen in 
the heat map 
(Figure 4), PCR 
was performed to analyze the status of the floxed Brca1 alleles in tissues from 
representative BPP mice. Figure 7 shows the PCR analysis of Brca1 status in DNA 
isolated from representative tumors arising in BPP mice (Supplemental Figure S2) 
compared to their corresponding tail DNA. In these cases, PCR of tail DNA confirmed 
the presence of only floxed Brca1 alleles. However, in the tumor samples there was 
incomplete deletion of Brca1.  
 
 
 
 
 
 
 
 
 
Figure 7: PCR analysis of tail (t) DNA paired with tumor (T) DNA from BPP mice. Primers 
were used to detect floxed, wild type or deleted Brca1 alleles in these samples.  LT and 
RT represent left and right tumors from mouse 15195. 
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Discussion  
The purpose of this research was to test how well mouse models of HGSC match 
to the molecular features of HGSCs arising in humans.  Mouse models that closely 
mimic their human counterparts can be used to test new strategies for early detection 
and prevention of HGSC.   
Mice were first analyzed in order to see which combinations of inactivated genes 
would lead to oviductal tumors. They were placed into categories including BPP, BPN, 
or BPRN depending on the genes targeted for floxed deletion. These data were used to 
select tumor samples from lesions in paired oviducts, as well as from metastases 
regions, while comparing them to controls. The samples were then subjected to NGS to 
measure copy number changes of the 32 most commonly mutated genes in HGSC [10].  
HGSC, like other cancers, results in genetic instability in both human and mouse 
models. As predicted, this was seen in the results of the NGS data by widespread 
alterations to copy numbers in these genes of interest.  
Figure 4 indicates widespread deletions of the floxed genes in BPRN mice which 
cluster together on the chart. It also shows a significant clustering of BPP, APA, and 
normal samples. The BPP and APA mice also show that the targeted regions were 
deleted as expected, as seen by dark bands of blue corresponding to copy number 
loses in those cases. The data also show that tumors from these mice acquired 
additional changes that coincide with data observed in human HGSCs, including 
amplification of cMyc and deletion of Pten.   
The deletion of Pten was first confirmed with PCR. As shown in Figure 5, a 
BPRN mouse, 14433, appeared to have spontaneously lost the Pten gene in the tumor 
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and metastases samples since there is no band corresponding to the wild type allele of 
the gene. Comparing this to the sample of normal tissue, however, it is clear that this 
was a specific deletion acquired by only the cancerous regions. The normal sample 
retained the band for Pten. In addition, mouse 2405, which was categorized as BPN, 
appeared to also have lost copies of Pten according to the heat map. Once again, a 
comparison of the tumor to a normal tissue sample from the mouse confirmed the 
presence of the wild type allele only in the normal sample and was lacking in the tumor 
sample.  
Furthermore, IHC staining was done to look at the expression of the gene. Figure 
6 shows representative sections from 4 different mice: 6A an APA mouse, 6B a BPP 
mouse, 6C a BPRN mouse identified as having lost copies of Pten according to the heat 
map, and 6D a positive control with known Pten expression. Since Pten had been 
targeted for deletion in both the APA mouse as well as the BPP mouse, it was predicted 
that there would be very little positive staining in these two samples. Figure 6C was a 
sample derived from the same mouse that was checked with PCR for loss of Pten. 
Since this sample too showed very little staining compared to the positive control, the 
data from the heat map were corroborated demonstrating that even in samples that 
were not targeted for Pten deletion, the tumors selected for cells with less copies of this 
gene. Thus the mouse HGSCs followed the same pattern as human HGSCs and the 
tumors were found to have spontaneously lost copies of this gene. This adds to the 
conclusion that our mouse model of HGSC does indeed correlate with the genetic 
profile and progression of the human model.  
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Another area of the interest on the heat map was where the BPP mice clustered. 
The samples showed a surprisingly weak loss of Brca1 even though it was targeted for 
deletion for Cre recombinase. Figure 7 shows the confirmation of this incomplete 
deletion by PCR analysis. DNA from BPP tumors (T) as well as DNA from the mouse 
tail DNA (t) were compared using primers specific for Brca1. Again confirming the 
results of the heat map, bands from the tumors appeared that corresponded to the wild 
type, floxed and deleted alleles. By contrast, normal DNA from the same mice appeared 
to only have bands corresponding to floxed portions of the gene—which is expected 
since Cre recombinase targeted the oviducts for Brca1 deletion. We conclude that since 
Brca1 deletion is not strongly selected for in BPP mice, the loss of this gene is not 
necessary for tumor formation. In our BPP model system, deletion of Pten and Trp53 
appears to be sufficient to drive tumorigenesis.   
Understanding which genes are mutated, and when, may allow for earlier HGSC 
diagnosis.  For example, detection of tumor-specific DNA in routine Pap smears from 
women at high risk for developing HGSC could be used as an early detection strategy.  
Moreover, if tumor DNA is detected, the chances of metastasis could be determined 
based on knowledge of the general progression of the disease accompanied by 
accumulation of genetic mutations. Additional experiments will provide opportunities to 
explore these options and hopefully improve care for patients diagnosed with ovarian 
cancer. 
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Supplemental	Figure	S1:	
DNA	samples	from	Oviductal	
Tumors	in	TAM-treated	
BPRN,	BPR	and	BPN	mice	for	
targeted	sequencing.	
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Supplemental	Figure	S2:	Summary	of	Oviductal	Tumor	Phenotype	in	TAM-treated	BPP	mice		
	
